Unknown

Dataset Information

0

Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.


ABSTRACT: miR-29b directly or indirectly targets genes involved in acute myeloid leukemia (AML), namely, DNMTs, CDK6, SP1, KIT, and FLT3. Higher miR-29b pretreatment expression is associated with improved response to decitabine and better outcome in AML. Thus, designing a strategy to increase miR-29b levels in AML blasts may be of therapeutic value. However, free synthetic miRs are easily degraded in bio-fluids and have limited cellular uptake. To overcome these limitations, we developed a novel transferrin-conjugated nanoparticle delivery system for synthetic miR-29b (Tf-NP-miR-29b).Delivery efficiency was investigated by flow cytometry, confocal microscopy, and quantitative PCR. The expression of miR-29b targets was measured by immunoblotting. The antileukemic activity of Tf-NP-miR-29b was evaluated by measuring cell proliferation and colony formation ability and in a leukemia mouse model.Tf-NP-miR-29b treatment resulted in more than 200-fold increase of mature miR-29b compared with free miR-29b and was approximately twice as efficient as treatment with non-transferrin-conjugated NP-miR-29b. Tf-NP-miR-29b treatment significantly downregulated DNMTs, CDK6, SP1, KIT, and FLT3 and decreased AML cell growth by 30% to 50% and impaired colony formation by approximately 50%. Mice engrafted with AML cells and then treated with Tf-NP-miR-29b had significantly longer survival compared with Tf-NP-scramble (P = 0.015) or free miR-29b (P = 0.003). Furthermore, priming AML cell with Tf-NP-miR-29b before treatment with decitabine resulted in marked decrease in cell viability in vitro and showed improved antileukemic activity compared with decitabine alone (P = 0.001) in vivo.Tf-NP effectively delivered functional miR-29b, resulting in target downregulation and antileukemic activity and warrants further investigation as a novel therapeutic approach in AML.

SUBMITTER: Huang X 

PROVIDER: S-EPMC3644023 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeted delivery of microRNA-29b by transferrin-conjugated anionic lipopolyplex nanoparticles: a novel therapeutic strategy in acute myeloid leukemia.

Huang Xiaomeng X   Schwind Sebastian S   Yu Bo B   Santhanam Ramasamy R   Wang Hongyan H   Hoellerbauer Pia P   Mims Alice A   Klisovic Rebecca R   Walker Alison R AR   Chan Kenneth K KK   Blum William W   Perrotti Danilo D   Byrd John C JC   Bloomfield Clara D CD   Caligiuri Michael A MA   Lee Robert J RJ   Garzon Ramiro R   Muthusamy Natarajan N   Lee Ly James LJ   Marcucci Guido G  

Clinical cancer research : an official journal of the American Association for Cancer Research 20130314 9


<h4>Purpose</h4>miR-29b directly or indirectly targets genes involved in acute myeloid leukemia (AML), namely, DNMTs, CDK6, SP1, KIT, and FLT3. Higher miR-29b pretreatment expression is associated with improved response to decitabine and better outcome in AML. Thus, designing a strategy to increase miR-29b levels in AML blasts may be of therapeutic value. However, free synthetic miRs are easily degraded in bio-fluids and have limited cellular uptake. To overcome these limitations, we developed a  ...[more]

Similar Datasets

| S-EPMC4342499 | biostudies-literature
| S-EPMC5127669 | biostudies-literature
| S-EPMC7698888 | biostudies-literature
| S-EPMC3650246 | biostudies-literature
| S-EPMC2917066 | biostudies-literature
2011-03-16 | E-TABM-944 | biostudies-arrayexpress
| S-EPMC6723634 | biostudies-literature
| S-EPMC2710934 | biostudies-literature
| S-EPMC6410246 | biostudies-literature
| S-EPMC9169767 | biostudies-literature